Thrombosis with Thrombocytopenia Syndrome (TTS) is a rare but severe clotting disorder. While TTS is rare, certain COVID-19 vaccines , particularly those based on adenoviral vectors, have been associated with an increased risk of TTS events in some individuals. This syndrome involves blood clot formation (thrombosis) accompanied by low platelet levels (thrombocytopenia), often occurring within a few weeks of vaccination. While the occurrence of TTS post-vaccination is exceedingly rare, it sparked global concern and led to thorough investigations by health authorities. The exact mechanism behind TTS is still under investigation, but it is believed to involve an immune-mediated response triggered by the vaccine, leading to the formation of antibodies that activate platelets, culminating in clot formation and platelet consumption. Symptoms of TTS can vary depending on the location and severity of blood clots. Common signs may include: Severe headaches or migraines Abdominal pain or swell